CNSP vs. RLAY, TYRA, SANA, DNTH, GHRS, VALN, ABUS, PHAR, LENZ, and CRMD
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Sana Biotechnology (SANA), Dianthus Therapeutics (DNTH), GH Research (GHRS), Valneva (VALN), Arbutus Biopharma (ABUS), Pharming Group (PHAR), LENZ Therapeutics (LENZ), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.
CNS Pharmaceuticals vs.
CNS Pharmaceuticals (NASDAQ:CNSP) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
CNS Pharmaceuticals has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics received 13 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 71.64% of users gave CNS Pharmaceuticals an outperform vote while only 70.11% of users gave Relay Therapeutics an outperform vote.
In the previous week, Relay Therapeutics had 12 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 17 mentions for Relay Therapeutics and 5 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.31 beat Relay Therapeutics' score of 0.13 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.
CNS Pharmaceuticals has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
CNS Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 1,122.49%. Relay Therapeutics has a consensus price target of $19.80, suggesting a potential upside of 546.00%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe CNS Pharmaceuticals is more favorable than Relay Therapeutics.
CNS Pharmaceuticals' return on equity of 0.00% beat Relay Therapeutics' return on equity.
14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 0.1% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
CNS Pharmaceuticals beats Relay Therapeutics on 9 of the 17 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNSP) was last updated on 3/4/2025 by MarketBeat.com Staff
